Some studies have suggested that LKB1 loss promotes tumor proliferation by altering the NKX2-1/p53 pathway46 and that loss of the LKB1-AMPK signaling pathway is associated with prognosis in patients undergoing advanced non-small cell lung cancer chemotherapy47. Here, NKX2-1 is linked to non-small cell lung carcinoma.